JP2022513320A - Ｆｌｔ３が変異した血液のがんを処置する方法 - Google Patents

Ｆｌｔ３が変異した血液のがんを処置する方法 Download PDF

Info

Publication number
JP2022513320A
JP2022513320A JP2021542090A JP2021542090A JP2022513320A JP 2022513320 A JP2022513320 A JP 2022513320A JP 2021542090 A JP2021542090 A JP 2021542090A JP 2021542090 A JP2021542090 A JP 2021542090A JP 2022513320 A JP2022513320 A JP 2022513320A
Authority
JP
Japan
Prior art keywords
mutation
flt3
itd
pharmaceutically acceptable
tkd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513320A5 (https=
Inventor
バヴァナ バトナガー，
シャーリン ディー． ベイカー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
CTI Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTI Biopharma Corp filed Critical CTI Biopharma Corp
Publication of JP2022513320A publication Critical patent/JP2022513320A/ja
Publication of JP2022513320A5 publication Critical patent/JP2022513320A5/ja
Priority to JP2024106255A priority Critical patent/JP2024114967A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021542090A 2018-10-01 2019-10-01 Ｆｌｔ３が変異した血液のがんを処置する方法 Pending JP2022513320A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024106255A JP2024114967A (ja) 2018-10-01 2024-07-01 Ｆｌｔ３が変異した血液のがんを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862739802P 2018-10-01 2018-10-01
US62/739,802 2018-10-01
US201962838239P 2019-04-24 2019-04-24
US62/838,239 2019-04-24
PCT/US2019/054142 WO2020072544A1 (en) 2018-10-01 2019-10-01 Methods of treating flt3-mutated hematologic cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024106255A Division JP2024114967A (ja) 2018-10-01 2024-07-01 Ｆｌｔ３が変異した血液のがんを処置する方法

Publications (2)

Publication Number Publication Date
JP2022513320A true JP2022513320A (ja) 2022-02-07
JP2022513320A5 JP2022513320A5 (https=) 2022-10-12

Family

ID=70054475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542090A Pending JP2022513320A (ja) 2018-10-01 2019-10-01 Ｆｌｔ３が変異した血液のがんを処置する方法
JP2024106255A Pending JP2024114967A (ja) 2018-10-01 2024-07-01 Ｆｌｔ３が変異した血液のがんを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024106255A Pending JP2024114967A (ja) 2018-10-01 2024-07-01 Ｆｌｔ３が変異した血液のがんを処置する方法

Country Status (4)

Country Link
US (2) US20220008448A1 (https=)
EP (1) EP3860655A4 (https=)
JP (2) JP2022513320A (https=)
WO (1) WO2020072544A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113502332B (zh) * 2021-09-07 2021-12-17 广东永诺医疗科技有限公司 一种用于检测flt3基因突变的引物、探针及试剂盒
US20250049787A1 (en) * 2021-12-22 2025-02-13 University Health Network Treatment for acute myeloid leukemia or lymphoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112846A1 (en) * 2005-11-16 2017-04-27 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives
ES2811804T3 (es) * 2013-10-31 2021-03-15 Biokine Therapeutics Ltd Un inhibidor peptídico de CXCR4 para su uso en el tratamiento de la leucemia mieloide aguda con una mutación de FLT3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112846A1 (en) * 2005-11-16 2017-04-27 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANG, E. ET AL.: "The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/IT", LEUKEMIA, vol. 30, no. 5, JPN6023036574, pages 1025 - 32, ISSN: 0005273013 *
HART, S. ET AL.: "SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoi", LEUKEMIA, vol. 25, JPN6023036575, 2011, pages 1751 - 1759, ISSN: 0005273012 *
KNAPPER, S. ET AL.: "AN EVALUATION OF THE TYROSINE KINASE INHIBITOR PACRITINIB IN PATIENTS WITH RELAPSED FLT3-MUTATED ACU", THE UK NCRI AML17 STUDY, JPN6023036576, 2016, ISSN: 0005273011 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 377, JPN6023036573, 2017, pages 454 - 464, ISSN: 0005273014 *

Also Published As

Publication number Publication date
US20250319111A1 (en) 2025-10-16
EP3860655A4 (en) 2022-08-03
WO2020072544A1 (en) 2020-04-09
US20220008448A1 (en) 2022-01-13
JP2024114967A (ja) 2024-08-23
EP3860655A1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
KR101633134B1 (ko) 시티딘 유사체의 경구 제형 및 그의 사용 방법
US20220249528A1 (en) Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
JP6063628B2 (ja) ５−アザシチジンを用いる、非小細胞肺癌の治療方法
CN115515577A (zh) 用于治疗癌症的atr抑制剂
US20250319111A1 (en) Methods of treating flt3-mutated hematologic cancers
KR20170045237A (ko) 항-pd1 또는 항-pdl1 단클론성 항체와 조합된 시티딘 유사체의 경구 제제를 사용한 질환 또는 장애를 치료하는 방법
EA028462B1 (ru) Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
CN104168884A (zh) 使用胞苷类似物的口服制剂治疗癌症的方法
US20230346772A1 (en) Combination treatments for waldenstrom's macroglobulinemia
TW202332444A (zh) 用於治療癌症之醫藥組成物
JP2024038485A (ja) 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
TW202231283A (zh) 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療
US20110151020A1 (en) Active substance combination with gemcitabine for the treatment of epithelial cancer
CN115335060A (zh) 使用突变idh抑制剂的组合疗法
CA2849903A1 (en) Combination therapy for chemoresistant cancers
BR112021011493A2 (pt) Terapia de combinação para tratamento de câncer
US20240165112A1 (en) Therapy for the treatment of cancer
TW202545533A (zh) 在組合療法中使用menin抑制劑治療急性白血病之方法
WO2019006133A1 (en) METHODS OF DELAYING AND PREVENTING RECHUTE FROM ACUTE MYELOID LEUKEMIA
CN118201622A (zh) 用地西他滨和西达尿苷治疗骨髓增生异常综合征的方法
WO2021079129A1 (en) Dosing regimen
WO2023046307A1 (en) [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
KR20160035067A (ko) 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 아자시티딘과 병용된 볼라세르티브
JP7519657B2 (ja) 慢性骨髄性白血病幹細胞阻害剤
US20090239878A1 (en) Combinations of (a) an atp-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240301